SCHEMBL4455329

SCHEMBL4455329

Cc1cc(C(=O)O)c(C2CCN(C(=O)OC(C)(C)C)CC2)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
HPGD P15428 3/20 0.51
HSD17B10 Q99714 3/20 0.51
NPSR1 Q6W5P4 3/20 0.51
USP2 O75604 2/20 0.51
KDM4E B2RXH2 3/20 0.48
MAPT P10636 3/20 0.48
THRB P10828 1/20 0.48
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.46
CRHBP P24387 1/20 0.46
HTT P42858 1/20 0.46
CRHR2 Q13324 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 2/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GPR119 Q8TDV5 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13671300 0.91 MAPT (0.48) KMT2AMEN1HPGDHSD17B10NPSR1
SCHEMBL13671236 0.88 MAPT (0.46) KMT2AMEN1HPGDHSD17B10NPSR1
SCHEMBL13671244 0.85 MAPT (0.49) KMT2AMEN1HPGDHSD17B10NPSR1
SCHEMBL19702760 0.84 MAPT (0.53) KMT2AMEN1HPGDHSD17B10NPSR1
SCHEMBL23216278 0.84 ADAM17 (0.48) KMT2AMEN1KDM4EMAPTTHRB
SCHEMBL29768430 0.84 ADAM17 (0.48) KMT2AMEN1KDM4EMAPTTHRB
SCHEMBL4004428 0.83 MAPT (0.47) KMT2AMEN1HPGDHSD17B10NPSR1
SCHEMBL4465793 0.83 MAPT (0.47) KMT2AMEN1HPGDHSD17B10NPSR1
SCHEMBL8223129 0.82 MEN1 (0.60) KMT2AMEN1HPGDHSD17B10NPSR1
SCHEMBL31342620 0.82 MAPT (0.49) KMT2AMEN1NPSR1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253744-A1 Acylated piperidine derivatives as melanocortin-4 receptor modulators MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253744-A1 Acylated piperidine derivatives as melanocortin-4 receptor modulators MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253744-A1 Acylated piperidine derivatives as melanocortin-4 receptor modulators MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
WO-2008039418-A2 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253744-A1 Acylated piperidine derivatives as melanocortin-4 receptor modulators MC4R, MC5R, MC3R KMT2A 914/4885MEN1 2383/4885HPGD 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.